Prosper Medical Raises $16M Seed for AI-Enabled Primary Care

Prosper Medical has raised a $16M seed round to expand an AI-enabled concierge primary care model built around dedicated physicians, care coordination, and continuous patient context. FUSE led the financing, with Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures, and Western Technology Investment participating.

Co-founders Ryan McQuaid and James Wantuck, MD, are returning to a problem they know well. After building PlushCare around easier access to virtual care, they are now focusing on what happens before, between, and after appointments: medical records, laboratory results, specialist referrals, medication management, follow-up, and the slow work of maintaining a long-term physician relationship.

The broader wager extends well beyond another healthcare chatbot. Prosper Medical is testing whether AI can reduce the coordination costs of high-touch primary care while keeping physicians responsible for clinical decisions, a much harder operating model than simply replacing a waiting room with a video visit.

What Happened

Prosper Medical announced the seed financing on July 23, 2026. The company said it will use the capital to expand its physician network, continue developing the AI platform underlying its care model, and enter additional markets.

The company has not disclosed a valuation, previous financing rounds, or a verified lifetime funding total. It also has not published hiring targets or market-by-market expansion plans, meaning the $16M establishes direction and runway without revealing how quickly the network is expected to grow.

The investor group combines FUSE with Western Technology Investment, a venture debt provider, alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, and Knoll Ventures. That mix gives Prosper Medical investors with experience across early-stage technology, healthcare, and growth financing, although the company did not disclose the financing structure or detailed investment terms.

The Founders Are Not New to Virtual Care

Ryan McQuaid, Prosper Medical's Co-Founder and CEO, and James Wantuck, MD, its Co-Founder and Chief Medical Officer, previously co-founded PlushCare. In 2021, Accolade announced an agreement to acquire PlushCare for consideration valued at up to $450M, giving the founders direct experience building physician networks, managing insurance relationships, operating virtual-care services nationally, and earning consumer trust.

That history matters because access and continuity are fundamentally different businesses. Telehealth solved scheduling and geographic barriers, but it often left patients responsible for connecting records, referrals, diagnostic tests, medications, and a new clinician's understanding of their medical history.

Prosper Medical is built around the argument that primary care becomes more valuable when patient context survives the appointment itself. Previous success does not guarantee this model will retain members or improve practice economics, but it does mean the founding team has already experienced the operational complexity hidden behind a simple appointment screen.

The Product Is Selling Continuity, Not Just Access

Prosper Medical's $69 monthly membership includes messaging, care concierge support, medical-record collection, laboratory coordination, prescription management, and access to a dedicated physician team. Clinical visits are billed separately through eligible PPO insurance with standard cost sharing, while the company's support materials list a $129 cash-pay option.

The AI platform is designed to unify laboratory results, medical records, medications, and patient messages, prepare physicians before appointments, explain health information, and identify follow-up needs. Prosper Medical presents the technology as physician support rather than physician replacement, positioning the product closer to an AI-enabled medical practice than a standalone symptom checker.

The company says it is available in all 50 states, accepts many major insurance plans, and has served thousands of members during its first few months of operation. Those are company-reported figures rather than independently audited operating metrics, and Prosper Medical has not published retention rates, clinical outcomes, revenue, or member acquisition and servicing costs.

Why This Matters

Concierge medicine has traditionally created more physician time and attention by charging premium membership fees that naturally limit the patient population. Prosper Medical is attempting to change that equation through a relatively modest membership fee, insurance-backed physician visits, centralized care coordination, and software that absorbs routine administrative work.

That is a more credible application of AI than treating physicians as an outdated dependency. Many of the most expensive failures in primary care stem not from missing information but from missing continuity: no one owns follow-up, data remains fragmented across systems, and patients become their own care coordinators.

If Prosper Medical can successfully scale a dedicated-care model across a national physician network, it could establish a practical middle ground between episodic telehealth and traditional high-cost concierge medicine. If coordination costs grow as quickly as membership, however, the same model could become a service-heavy business with software layered on top.

What FUSE Is Betting On

FUSE General Partner Brendan Wales described the investment as a bet on McQuaid and Wantuck's experience earning patient trust at scale. The firm is backing founders who have already built a national virtual-care company and are now applying those operational lessons to a more relationship-driven model of primary care.

The investment thesis also reflects a broader shift in healthcare AI. The most valuable product may not be the loudest autonomous agent. It may instead be the infrastructure that gives physicians better patient context, prevents patients from repeating the same medical history, and makes each clinical decision more informed and less fragmented.

That thesis still carries significant execution risk because healthcare remains highly regulated, operationally complex, and fundamentally dependent on human judgment. Prosper Medical has not publicly detailed its underlying AI models, technology stack, formal clinical validation, or the governance and escalation processes surrounding AI-generated recommendations.

What to Watch

The next proof points include physician-network growth, member retention, care quality, insurance coverage, and evidence that the AI platform improves care coordination without introducing new clinical or administrative failure points. Investors and healthcare operators should also watch whether Prosper Medical can preserve meaningful physician relationships as it expands beyond its first few thousand company-reported members.

The $16M financing gives Prosper Medical more room to test that balance. The company is not simply asking whether patients will interact with AI about their health. It is asking whether AI can help real physicians know their patients better, and whether that relationship can ultimately scale without becoming another luxury service.